Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has been added to both the Russell 2000® and Russell 3000® Indexes following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.
The inclusion comes as part of FTSE Russell's annual reconstitution process, which ranks the 4,000 largest US stocks by market capitalization. Notably, approximately $10.6 trillion in assets are benchmarked against Russell US indexes as of June 2024. Membership in these indexes will remain in place for one year.
Aclaris Therapeutics (NASDAQ: ACRS), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per malattie immuno-infiammatorie, è stata inclusa sia negli indici Russell 2000® e Russell 3000® a seguito della ristrutturazione annuale degli indici Russell USA 2025, con decorrenza dal 30 giugno 2025.
L'inclusione fa parte del processo annuale di ristrutturazione di FTSE Russell, che classifica le 4.000 maggiori azioni statunitensi in base alla capitalizzazione di mercato. È importante sottolineare che circa 10,6 trilioni di dollari in asset sono indicizzati sugli indici Russell USA a giugno 2024. L'appartenenza a questi indici rimarrà valida per un anno.
Aclaris Therapeutics (NASDAQ: ACRS), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades inmuno-inflamatorias, ha sido incluida en los índices Russell 2000® y Russell 3000® tras la reconstitución anual de los índices Russell de EE. UU. 2025, efectiva a partir del 30 de junio de 2025.
Esta inclusión forma parte del proceso anual de reconstitución de FTSE Russell, que clasifica las 4,000 mayores acciones estadounidenses según su capitalización de mercado. Cabe destacar que aproximadamente 10.6 billones de dólares en activos están referenciados a los índices Russell de EE. UU. a junio de 2024. La membresía en estos índices se mantendrá durante un año.
Aclaris Therapeutics (NASDAQ: ACRS)는 면역 염증 질환 치료에 특화된 임상 단계 바이오제약 회사로, 2025년 러셀 미국 지수 연례 재구성에 따라 러셀 2000® 및 러셀 3000® 지수에 각각 편입되어 2025년 6월 30일부터 적용됩니다.
이번 편입은 FTSE 러셀의 연례 재구성 절차의 일환으로, 시가총액 기준 미국 내 상위 4,000개 주식을 순위 매깁니다. 2024년 6월 기준 약 10.6조 달러 규모의 자산이 러셀 미국 지수를 벤치마크로 사용하고 있습니다. 해당 지수 내 편입은 1년간 유지됩니다.
Aclaris Therapeutics (NASDAQ: ACRS), une société biopharmaceutique en phase clinique spécialisée dans les traitements des maladies immuno-inflammatoires, a été ajoutée aux indices Russell 2000® et Russell 3000® suite à la reconstitution annuelle des indices Russell US 2025, effective au 30 juin 2025.
Cette inclusion fait partie du processus annuel de reconstitution de FTSE Russell, qui classe les 4 000 plus grandes actions américaines selon leur capitalisation boursière. Il est à noter qu'environ 10,6 billions de dollars d'actifs sont référencés aux indices Russell US en juin 2024. L'appartenance à ces indices sera maintenue pendant un an.
Aclaris Therapeutics (NASDAQ: ACRS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Behandlung immun-entzündlicher Erkrankungen spezialisiert hat, wurde nach der jährlichen Neuzusammensetzung der Russell US-Indizes 2025 in die Russell 2000® und Russell 3000® Indizes aufgenommen, wirksam ab dem 30. Juni 2025.
Die Aufnahme erfolgt im Rahmen des jährlichen Neuzusammensetzungsprozesses von FTSE Russell, der die 4.000 größten US-Aktien nach Marktkapitalisierung bewertet. Bemerkenswert ist, dass zum Stand Juni 2024 etwa 10,6 Billionen US-Dollar an Vermögenswerten an den Russell US-Indizes ausgerichtet sind. Die Mitgliedschaft in diesen Indizes bleibt für ein Jahr bestehen.
- Inclusion in widely-tracked Russell 2000® and Russell 3000® Indexes increases visibility to institutional investors
- Potential for increased trading volume and liquidity due to index fund purchases
- Recognition of company's market capitalization growth to qualify for these indexes
- None.
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025.
The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about
For more information on the Russell 3000® Index, the Russell 2000® index, and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
When was Aclaris Therapeutics (ACRS) added to the Russell 2000 and Russell 3000 indexes?
What are the requirements for Aclaris Therapeutics to be included in the Russell indexes?
How much in assets are benchmarked against Russell US indexes?
What is Aclaris Therapeutics' main business focus?
How long will Aclaris Therapeutics remain in the Russell indexes?
